Cigna Group (CI) is a large-cap U.S.-based insurance provider with a market cap of $74.4 billion. Despite a recent decline in stock value, the company offers a wide range of health-related products and services, including pharmacy and care management solutions, medical and behavioral health coverage, Medicare plans, and international health benefits. Cigna’s stock has been underperforming compared to the Nasdaq Composite, but analysts remain optimistic about its future, giving it a consensus rating of “Strong Buy” and a mean price target of $329.45, an 18.4% premium to current levels.

On the other hand, rival UnitedHealth Group Incorporated (UNH) has seen a significant decline in stock value, dropping 34.8% on a YTD basis and 45.7% over the past 52 weeks. Despite reporting better-than-expected Q3 2025 adjusted EPS and revenue, Cigna’s shares tumbled 17.4% due to warnings of significant margin pressure over the next two years in its pharmacy benefit services segment. This pressure is a result of the company’s shift to a no-rebate pricing model and the repricing of major contracts, impacting about $90 billion in annual revenue.

Read more at Yahoo Finance: Is Cigna Stock Underperforming the Nasdaq?